Vitamin K Antagonists Predispose to Calciphylaxis in Patients width End-Stage Renal Disease

被引:43
作者
Galloway, Peter A. G. [1 ]
El-Damanawi, Ragada [1 ]
Bardsley, Victoria [3 ]
Pritchard, Nicholas R. [2 ]
Fry, Andrew C. [2 ]
Ojha, Sanjay K. [2 ]
Hiemstra, Thomas F. [1 ,2 ]
机构
[1] Univ Cambridge, Sch Clin Med, Cambridge, England
[2] Addenbrookes Hosp, Div Renal Med, Cambridge CB2 0QQ, England
[3] Addenbrookes Hosp, Dept Histopathol, Cambridge CB2 0QQ, England
关键词
Calciphylaxis; Calcific; Uremic; Arteriolopathy; Warfarin; Dialysis; VASCULAR CALCIFICATION; RISK-FACTORS; WARFARIN; HEMODIALYSIS; SURVIVAL;
D O I
10.1159/000371449
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background/Aims: Calciphylaxis is associated with a poor prognosis in dialysis patients, and its pathogenesis remains incompletely understood. Although the use of vitamin K antagonists (VKA) has been implicated, previous reports are conflicting. We aimed to determine if vitamin K antagonists conferred an increased risk of calciphylaxis in patients on dialysis. Methods: We performed a single-centre, retrospective cohort study of 2,234 patients receiving dialysis, and compared the characteristics of those with and without calciphylaxis. Results: We identified 5 cases of calciphylaxis (all female) between January 2009 and December 2013. Overall, 142 patients (6.4%) were treated with VKA during the study period. Calciphylaxis was more common in the VKA group (4 of 142 patients, OR = 61, 95% CI 6.7-546, p = 0.0001). VKA was withdrawn in all cases and treatment instituted with sodium thiosulphate, cinacalcet and supportive measures. All patients recovered, although there was one sudden cerebrovascular death during follow-up. Conclusion: Treatment with VKA predisposes to the development of calciphylaxis. (C) 2015 S. Karger AG, Basel
引用
收藏
页码:197 / 201
页数:5
相关论文
共 21 条
[1]   Calciphylaxis in patients on hemodialysis: A prevalence study [J].
Angelis, M ;
Wong, LL ;
Myers, SA ;
Wong, LM .
SURGERY, 1997, 122 (06) :1083-1089
[2]  
Angelis M, 1997, SURGERY, V122, P1089
[3]   Calciphylaxis in a diabetic patient provoked by warfarin therapy [J].
Asobie, N. ;
Wong, E. ;
Cook, M. G. .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2008, 33 (03) :342-344
[4]   Quercetin Attenuates Warfarin-induced Vascular Calcification in Vitro Independently from Matrix Gla Protein [J].
Beazley, Kelly E. ;
Eghtesad, Saman ;
Nurminskaya, Maria V. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (04) :2632-2640
[5]   Calciphylaxis: a still unmet challenge [J].
Brandenburg, Vincent M. ;
Cozzolino, Mario ;
Ketteler, Markus .
JOURNAL OF NEPHROLOGY, 2011, 24 (02) :142-148
[6]   Heparin, warfarin, or calciphylaxis? [J].
Crotty, Rory ;
Nazarian, Rosalynn M. ;
Song, Philip I. ;
Van Cott, Elizabeth M. .
AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (07) :785-786
[7]   Calciphylaxis is usually non-ulcerating: Risk factors, outcome and therapy [J].
Fine, A ;
Zacharias, J .
KIDNEY INTERNATIONAL, 2002, 61 (06) :2210-2217
[8]   Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): a rationale and study protocol [J].
Krueger, Thilo ;
Schlieper, Georg ;
Schurgers, Leon ;
Cornelis, Tom ;
Cozzolino, Mario ;
Jacobi, Johannes ;
Jadoul, Michel ;
Ketteler, Markus ;
Rump, Lars C. ;
Stenvinkel, Peter ;
Westenfeld, Ralf ;
Wiecek, Andrzej ;
Reinartz, Sebastian ;
Hilgers, Ralf-Dieter ;
Floege, Juergen .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 (09) :1633-1638
[9]   Determinants of survival in patients with calciphylaxis: A multivariate analysis [J].
Lal, Geeta ;
Nowell, Andrew G. ;
Liao, Junlin ;
Sugg, Sonia L. ;
Weigel, Ronald J. ;
Howe, James R. .
SURGERY, 2009, 146 (06) :1028-1034
[10]   Risk factors and mortality associated with calciphylaxis in end-stage renal disease [J].
Mazhar, AR ;
Johnson, RJ ;
Gillen, D ;
Stivelman, JC ;
Ryan, MJ ;
Davis, CL ;
Stehman-Breen, CO .
KIDNEY INTERNATIONAL, 2001, 60 (01) :324-332